Longevity study with low doses of selegiline/(−)-deprenyl and (2R)-1-(1-benzofuran-2-yl)-N-propylpentane-2-amine (BPAP)

J. Knoll, I. Miklya

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Aims: The first longevity study demonstrating that rats treated with the MAO-B inhibitory dose of (−)-deprenyl (0.25 mg/kg) lived significantly longer than their saline-treated peers was published in 1988, and corroborated in many papers. The recent findings that (−)-deprenyl is primarily a PEA-derived synthetic catecholaminergic activity enhancer substance; (2R)-1-(1-benzofuran-2-yl)-N-propylpentane-2-amine (BPAP) is a tryptamine-derived synthetic enhancer substance, initiated our first longevity study on rats with low enhancer doses of (−)-deprenyl and BPAP to test the enhancer effect's role in life extension. Main methods: We used the shuttle box technique for selecting the optimum doses of (−)-deprenyl and BPAP. (−)-Deprenyl exerts in rats in 0.001 mg/kg its ‘specific’ enhancer effect and in 0.1 mg/kg its ‘non-specific’ enhancer effect. BPAP exerts its ‘specific’ enhancer effect in 0.0001 mg/kg and its ‘non-specific’ enhancer effect in 0.05 mg/kg. Groups of male Wistar rats (N = 40) were treated subcutaneously from their 10th week until death, three times weekly, with saline (0.5 ml/kg), and the selected doses of (−)-deprenyl or BPAP, respectively. As an indicator of aging we tested the age-related changes in their learning ability. Key findings: Rats treated with 0.0001 or 0.05 mg/kg BPAP lived significantly longer than their saline treated peers (P < 0.02) and BPAP was more potent in extending rats' lifespan than (−)-deprenyl. 18-month-old rats treated with 0.0001 mg/kg BPAP were as good learners as 3-month-old saline treated rats. Significance The study revealed that the enhancer effect is responsible for life extension.

Original languageEnglish
Pages (from-to)32-38
Number of pages7
JournalLife Sciences
Volume167
DOIs
Publication statusPublished - Dec 15 2016

Fingerprint

Selegiline
Amines
Rats
Life Expectancy
Aptitude
Monoamine Oxidase
1-benzofuran
Wistar Rats
Learning
Aging of materials

Keywords

  • (2R)-1-(1-benzofuran-2-yl)-N-propylpentane-2-amine (BPAP)
  • Aging
  • Enhancer substances
  • Lifespan
  • Longevity study
  • Low dose treatment
  • Selegiline/(−)-deprenyl

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Longevity study with low doses of selegiline/(−)-deprenyl and (2R)-1-(1-benzofuran-2-yl)-N-propylpentane-2-amine (BPAP). / Knoll, J.; Miklya, I.

In: Life Sciences, Vol. 167, 15.12.2016, p. 32-38.

Research output: Contribution to journalArticle

@article{8811530fbea843e1aae4bd735052533a,
title = "Longevity study with low doses of selegiline/(−)-deprenyl and (2R)-1-(1-benzofuran-2-yl)-N-propylpentane-2-amine (BPAP)",
abstract = "Aims: The first longevity study demonstrating that rats treated with the MAO-B inhibitory dose of (−)-deprenyl (0.25 mg/kg) lived significantly longer than their saline-treated peers was published in 1988, and corroborated in many papers. The recent findings that (−)-deprenyl is primarily a PEA-derived synthetic catecholaminergic activity enhancer substance; (2R)-1-(1-benzofuran-2-yl)-N-propylpentane-2-amine (BPAP) is a tryptamine-derived synthetic enhancer substance, initiated our first longevity study on rats with low enhancer doses of (−)-deprenyl and BPAP to test the enhancer effect's role in life extension. Main methods: We used the shuttle box technique for selecting the optimum doses of (−)-deprenyl and BPAP. (−)-Deprenyl exerts in rats in 0.001 mg/kg its ‘specific’ enhancer effect and in 0.1 mg/kg its ‘non-specific’ enhancer effect. BPAP exerts its ‘specific’ enhancer effect in 0.0001 mg/kg and its ‘non-specific’ enhancer effect in 0.05 mg/kg. Groups of male Wistar rats (N = 40) were treated subcutaneously from their 10th week until death, three times weekly, with saline (0.5 ml/kg), and the selected doses of (−)-deprenyl or BPAP, respectively. As an indicator of aging we tested the age-related changes in their learning ability. Key findings: Rats treated with 0.0001 or 0.05 mg/kg BPAP lived significantly longer than their saline treated peers (P < 0.02) and BPAP was more potent in extending rats' lifespan than (−)-deprenyl. 18-month-old rats treated with 0.0001 mg/kg BPAP were as good learners as 3-month-old saline treated rats. Significance The study revealed that the enhancer effect is responsible for life extension.",
keywords = "(2R)-1-(1-benzofuran-2-yl)-N-propylpentane-2-amine (BPAP), Aging, Enhancer substances, Lifespan, Longevity study, Low dose treatment, Selegiline/(−)-deprenyl",
author = "J. Knoll and I. Miklya",
year = "2016",
month = "12",
day = "15",
doi = "10.1016/j.lfs.2016.10.023",
language = "English",
volume = "167",
pages = "32--38",
journal = "Life Sciences",
issn = "0024-3205",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Longevity study with low doses of selegiline/(−)-deprenyl and (2R)-1-(1-benzofuran-2-yl)-N-propylpentane-2-amine (BPAP)

AU - Knoll, J.

AU - Miklya, I.

PY - 2016/12/15

Y1 - 2016/12/15

N2 - Aims: The first longevity study demonstrating that rats treated with the MAO-B inhibitory dose of (−)-deprenyl (0.25 mg/kg) lived significantly longer than their saline-treated peers was published in 1988, and corroborated in many papers. The recent findings that (−)-deprenyl is primarily a PEA-derived synthetic catecholaminergic activity enhancer substance; (2R)-1-(1-benzofuran-2-yl)-N-propylpentane-2-amine (BPAP) is a tryptamine-derived synthetic enhancer substance, initiated our first longevity study on rats with low enhancer doses of (−)-deprenyl and BPAP to test the enhancer effect's role in life extension. Main methods: We used the shuttle box technique for selecting the optimum doses of (−)-deprenyl and BPAP. (−)-Deprenyl exerts in rats in 0.001 mg/kg its ‘specific’ enhancer effect and in 0.1 mg/kg its ‘non-specific’ enhancer effect. BPAP exerts its ‘specific’ enhancer effect in 0.0001 mg/kg and its ‘non-specific’ enhancer effect in 0.05 mg/kg. Groups of male Wistar rats (N = 40) were treated subcutaneously from their 10th week until death, three times weekly, with saline (0.5 ml/kg), and the selected doses of (−)-deprenyl or BPAP, respectively. As an indicator of aging we tested the age-related changes in their learning ability. Key findings: Rats treated with 0.0001 or 0.05 mg/kg BPAP lived significantly longer than their saline treated peers (P < 0.02) and BPAP was more potent in extending rats' lifespan than (−)-deprenyl. 18-month-old rats treated with 0.0001 mg/kg BPAP were as good learners as 3-month-old saline treated rats. Significance The study revealed that the enhancer effect is responsible for life extension.

AB - Aims: The first longevity study demonstrating that rats treated with the MAO-B inhibitory dose of (−)-deprenyl (0.25 mg/kg) lived significantly longer than their saline-treated peers was published in 1988, and corroborated in many papers. The recent findings that (−)-deprenyl is primarily a PEA-derived synthetic catecholaminergic activity enhancer substance; (2R)-1-(1-benzofuran-2-yl)-N-propylpentane-2-amine (BPAP) is a tryptamine-derived synthetic enhancer substance, initiated our first longevity study on rats with low enhancer doses of (−)-deprenyl and BPAP to test the enhancer effect's role in life extension. Main methods: We used the shuttle box technique for selecting the optimum doses of (−)-deprenyl and BPAP. (−)-Deprenyl exerts in rats in 0.001 mg/kg its ‘specific’ enhancer effect and in 0.1 mg/kg its ‘non-specific’ enhancer effect. BPAP exerts its ‘specific’ enhancer effect in 0.0001 mg/kg and its ‘non-specific’ enhancer effect in 0.05 mg/kg. Groups of male Wistar rats (N = 40) were treated subcutaneously from their 10th week until death, three times weekly, with saline (0.5 ml/kg), and the selected doses of (−)-deprenyl or BPAP, respectively. As an indicator of aging we tested the age-related changes in their learning ability. Key findings: Rats treated with 0.0001 or 0.05 mg/kg BPAP lived significantly longer than their saline treated peers (P < 0.02) and BPAP was more potent in extending rats' lifespan than (−)-deprenyl. 18-month-old rats treated with 0.0001 mg/kg BPAP were as good learners as 3-month-old saline treated rats. Significance The study revealed that the enhancer effect is responsible for life extension.

KW - (2R)-1-(1-benzofuran-2-yl)-N-propylpentane-2-amine (BPAP)

KW - Aging

KW - Enhancer substances

KW - Lifespan

KW - Longevity study

KW - Low dose treatment

KW - Selegiline/(−)-deprenyl

UR - http://www.scopus.com/inward/record.url?scp=84994803281&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994803281&partnerID=8YFLogxK

U2 - 10.1016/j.lfs.2016.10.023

DO - 10.1016/j.lfs.2016.10.023

M3 - Article

C2 - 27777099

AN - SCOPUS:84994803281

VL - 167

SP - 32

EP - 38

JO - Life Sciences

JF - Life Sciences

SN - 0024-3205

ER -